Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Survival rate of AIDS disease and mortality in HIV-infected patients in Hamadan, Iran: a registry-based retrospective cohort study (1997-2011).

Mirzaei M, Poorolajal J, Khazaei S, Saatchi M.

Int J STD AIDS. 2013 Nov;24(11):859-66. doi: 10.1177/0956462413486457. Epub 2013 Jul 19.

PMID:
23970604
2.

Predictors of mortality among HIV-infected women in Kigali, Rwanda.

Lindan CP, Allen S, Serufilira A, Lifson AR, Van de Perre P, Chen-Rundle A, Batungwanayo J, Nsengumuremyi F, Bogaerts J, Hulley S.

Ann Intern Med. 1992 Feb 15;116(4):320-8.

PMID:
1733389
3.

Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.

Sánchez JM, Ramos Amador JT, Fernández de Miguel S, González Tomée MI, Rojo Conejo P, Ferrnado Vivas P, Clemente Vivas J, Ruiz Contreras J, Nogales Espert A.

Pediatr Infect Dis J. 2003 Oct;22(10):863-7.

PMID:
14551485
4.

Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy.

Cohen MH, French AL, Benning L, Kovacs A, Anastos K, Young M, Minkoff H, Hessol NA.

Am J Med. 2002 Aug 1;113(2):91-8.

5.

Ten-year mortality trends among persons diagnosed with HIV infection in England and Wales in the era of antiretroviral therapy: AIDS remains a silent killer.

Simmons RD, Ciancio BC, Kall MM, Rice BD, Delpech VC.

HIV Med. 2013 Nov;14(10):596-604. doi: 10.1111/hiv.12045. Epub 2013 May 15.

7.
8.

Race, sex, drug use, and progression of human immunodeficiency virus disease.

Chaisson RE, Keruly JC, Moore RD.

N Engl J Med. 1995 Sep 21;333(12):751-6.

9.

[Analysis of death causes of 345 cases with HIV/AIDS in Guangdong area].

Huang LF, Tang XP, Cai WP, Lei CL, Zheng FC, Chen WL, Ye XX.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2013 Feb;27(1):57-60. Chinese.

PMID:
23855133
10.
11.

Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study.

Young J, De Geest S, Spirig R, Flepp M, Rickenbach M, Furrer H, Bernasconi E, Hirschel B, Telenti A, Vernazza P, Battegay M, Bucher HC; Swiss HIV Cohort Study Group.

BMJ. 2004 Jan 3;328(7430):15.

12.

Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era.

Sanmartin R, de Felipe E, Tor J, Sanvicens A, Barluenga E, Martinez E, Muga R, Jou A, Ojanguren I, López JJ, Clotet B, Tural C.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1235-43. Epub 2012 Apr 20.

PMID:
22443303
13.

Outcomes of human immunodeficiency virus-infected and -exposed children undergoing surgery--a prospective study.

Karpelowsky JS, Leva E, Kelley B, Numanoglu A, Rode H, Millar AJ.

J Pediatr Surg. 2009 Apr;44(4):681-7. doi: 10.1016/j.jpedsurg.2008.08.036.

PMID:
19361626
14.

Mortality and progression to AIDS after starting highly active antiretroviral therapy.

van Sighem AI, van de Wiel MA, Ghani AC, Jambroes M, Reiss P, Gyssens IC, Brinkman K, Lange JM, de Wolf F; ATHENA Cohort Study Group.

AIDS. 2003 Oct 17;17(15):2227-36.

PMID:
14523280
15.

All-cause mortality in hospitalized HIV-infected patients at an acute tertiary care hospital with a comprehensive outpatient HIV care program in New York City in the era of highly active antiretroviral therapy (HAART).

Kim JH, Psevdos G Jr, Gonzalez E, Singh S, Kilayko MC, Sharp V.

Infection. 2013 Apr;41(2):545-51. doi: 10.1007/s15010-012-0386-7. Epub 2012 Dec 21.

PMID:
23264096
16.

Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era.

Brady MT, Oleske JM, Williams PL, Elgie C, Mofenson LM, Dankner WM, Van Dyke RB; Pediatric AIDS Clinical Trials Group219/219C Team.

J Acquir Immune Defic Syndr. 2010 Jan;53(1):86-94. doi: 10.1097/QAI.0b013e3181b9869f.

17.

Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City.

Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV.

Ann Intern Med. 2006 Sep 19;145(6):397-406.

PMID:
16983127
18.

Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women.

Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, Hernández-Aguado I, Meyer L, Porter K, del Amo J; CASCADE Collaboration.

Am J Epidemiol. 2008 Sep 1;168(5):532-40. doi: 10.1093/aje/kwn179. Epub 2008 Jul 28.

19.

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.

20.

Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.

Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS.

CMAJ. 1999 Mar 9;160(5):659-65.

Items per page

Supplemental Content

Write to the Help Desk